Publication | Open Access
Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia
33
Citations
21
References
2019
Year
Preferential D3 AntagonistPsychiatryPsychotic DisorderMedicinePsychotropic MedicationPsychopharmacologySchizophreniaNeuropsychiatryPlacebo-controlled StudyAcute ExacerbationPharmacotherapySocial SciencesPharmacologyPsychopathology
| Year | Citations | |
|---|---|---|
Page 1
Page 1